ADIL
Adial Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.12
+6.91%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$20.89M
MomentumView details →
1D Return
+6.91%
YTD Return
+23.91%
RSI (14)
73.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$20.89M
RSI (14)
73.2
MomentumView details →
1D Return
+6.91%
YTD Return
+23.91%
SummaryUpdated Jun 1, 2026
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Charlottesville, Virginia. The company went public in July 2018 and focuses on developing therapeutic treatments for addiction and related disorders. Adial is currently advancing its lead drug candidate through late-stage clinical trials, representing a specialized approach to addressing substance use disorders through targeted pharmaceutical interventions.
Similar companies
Latest newsMore news →
Adial Pharmaceuticals granted an option to purchase 307,814 shares of common stock at $5.76 per share as a material inducement to employment, exempt under Section 4(a)(2) of the Securities Act and Regulation D.11d agoAdial Pharmaceuticals received a notice from Nasdaq on August 18, 2026, stating that the company no longer meets the minimum stockholders' equity requirement under Rule 5550(b)(1), and the company intends to submit a compliance plan by the required deadline to regain compliance, including seeking stockholder approval to convert outstanding Series A Non-Voting Convertible Preferred Stock.15d ago